Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 13

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Colorectal cancer metastatic+1

Recruiting

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Delcath Systems Inc.

Pancreatic carcinoma

Recruiting

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Amsterdam UMC Stichting

Triple negative breast cancer+2

Recruiting

Study on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Universita Degli Studi Di Padova

Ischaemic stroke

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:JX10
  • Sponsor:Corxel Pharmaceuticals Co. Ltd.

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcarnitine hydrochloride
  • Sponsor:Mario Negri Institute For Pharmacological Research

Lupus nephritis

Recruiting

Study on Obinutuzumab for Adolescents with Active Lupus Nephritis and Safety in Children Aged 5 to 12

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Acquired haemophilia

Recruiting

Evaluating denecimig as bleeding prophylaxis in adults with acquired haemophilia A

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Denecimig
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Huntington's disease

Recruiting

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.